A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism

Exclusion Criteria

• •1. Subjects who had Primary hyperparathyroidism;
• •2. Subjects with a history of acute renal failure;
• •3. Subjects with chronic gastrointestinal disease or severe liver disease with clinical symptoms;
• •4. Subjects with a history of unstable angina, grade III or IV congestive heart failure, and/or clinically meaningful arrhythmia;
• •5. Subjects with serum albumin \< 30g/L, serum hemaoglobin \< 85g/L, or serum transaminase higher than 2.5 times the upper limit of nomal;
• •6. Subjects with a history of malignancy;
• •7. Subjects who plan to undergo surgery during the study period;
• •8. Subjects with a history active granulomatous diseases;
• •9. Subject with a history of alcohol abuse and drug abuse;
• •10. Human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab) or Treponema pallidum antibody (TP-Ab) are positive;
• •11. Subjects who are allergic to the test drug and its ingredients or excipients;
• •12. Subjects who combined with systemic or systemic diseases that are not suitable for clinical trials;
• •13. Subjects who have participated in clinical trials of other drugs or devices;